Yi Kathy

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
15
Insider Sells Sum
$1.05M

Insider Activity of Yi Kathy

The largest sale of all time was on 2018-03-15 and amounted to 5000 shares of Sangamo Therapeutics, Inc. for $127,812.

Biography of Yi Kathy

No biography is available at this moment.

2019-05-15SaleSangamo Therapeutics, Inc.
SGMO
EVP & Chief Financial Officer
5,000
0.0043%
$10.00$50,000-11.78%
2019-04-15SaleSangamo Therapeutics, Inc.
SGMO
EVP & Chief Financial Officer
5,000
0.0044%
$12.11$60,550-22.2%
2019-03-15SaleSangamo Therapeutics, Inc.
SGMO
EVP & Chief Financial Officer
5,000
0.005%
$10.00$50,000-0.92%
2019-03-01SaleSangamo Therapeutics, Inc.
SGMO
EVP & Chief Financial Officer
5,000
0.0049%
$10.00$50,000-3.28%
2019-01-15SaleSangamo Therapeutics, Inc.
SGMO
SVP & Chief Financial Officer
5,000
0.0048%
$11.04$55,200-12.27%
2018-12-17SaleSangamo Therapeutics, Inc.
SGMO
SVP & Chief Financial Officer
5,000
0.0049%
$11.44$57,200-8.94%
2018-11-15SaleSangamo Therapeutics, Inc.
SGMO
SVP & Chief Financial Officer
5,000
0.0047%
$10.00$50,000+3.57%
2018-10-15SaleSangamo Therapeutics, Inc.
SGMO
SVP & Chief Financial Officer
5,000
0.0049%
$13.97$69,850-20.25%
2018-09-17SaleSangamo Therapeutics, Inc.
SGMO
SVP & Chief Financial Officer
5,000
0.0049%
$14.66$73,285-23.06%
2018-08-16SaleSangamo Therapeutics, Inc.
SGMO
SVP & Chief Financial Officer
5,000
0.0049%
$15.39$76,952-25.44%
2018-07-16SaleSangamo Therapeutics, Inc.
SGMO
SVP & Chief Financial Officer
5,000
0.0051%
$14.77$73,860-19.09%
2018-06-15SaleSangamo Therapeutics, Inc.
SGMO
SVP & Chief Financial Officer
5,000
0.0051%
$15.67$78,365-24.01%
2018-05-15SaleSangamo Therapeutics, Inc.
SGMO
SVP & Chief Financial Officer
5,000
0.0053%
$15.38$76,920-16.21%
2018-04-16SaleSangamo Therapeutics, Inc.
SGMO
SVP & Chief Financial Officer
5,000
0.0057%
$19.83$99,144-23.18%
2018-03-15SaleSangamo Therapeutics, Inc.
SGMO
SVP & Chief Financial Officer
5,000
0.0061%
$25.56$127,812-40.62%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.